Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
12
×
boston blog main
life sciences
national blog main
biotech
boston top stories
clinical trials
national top stories
deals
san francisco blog main
fda
investing
startups
new york blog main
san francisco top stories
atlas venture
decibel therapeutics
dna
dyne therapeutics
gene therapy
harvard university
hearing loss
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
rare disease drugs
regenerative medicine
roche
san diego blog main
480 biomedical
adeno-associated virus
agios therapeutics
akouos
aldehyde
aldeyra therapeutics
allergic conjunctivitis
allosteric
arsenal medical
astellas pharma
astellas pharmaceuticals
What
therapeutics
12
×
medicines
drug
developing
fda
ipo
new
ago
data
medicine
million
raised
startup
treat
approval
biotech
company
drugs
dyne
gene
genetic
hearing
loss
muscle
phase
puts
rare
regenerative
step
years
adding
address
adds
affects
aiming
aims
aldeyra
allosteric
americans
analytics
Language
unset
Current search:
boston
×
therapeutics
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
3 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M